(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 6.71% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Abbvie's revenue in 2025 is $57,367,000,000.On average, 7 Wall Street analysts forecast ABBV's revenue for 2025 to be $106,200,092,594,796, with the lowest ABBV revenue forecast at $105,436,513,660,688, and the highest ABBV revenue forecast at $108,219,250,230,930. On average, 7 Wall Street analysts forecast ABBV's revenue for 2026 to be $114,827,183,781,828, with the lowest ABBV revenue forecast at $112,367,962,159,578, and the highest ABBV revenue forecast at $118,935,137,727,031.
In 2027, ABBV is forecast to generate $123,058,743,769,457 in revenue, with the lowest revenue forecast at $119,846,912,575,896 and the highest revenue forecast at $127,590,646,805,961.